TGFβ signaling mediates microglial resilience to spatiotemporally restricted myelin degeneration.

Saved in:
Bibliographic Details
Title: TGFβ signaling mediates microglial resilience to spatiotemporally restricted myelin degeneration.
Authors: Zhu K; Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.; Department of Neurology, Division of Neuroimmunology and Glial Biology, University of California San Francisco, San Francisco, CA, USA., Liu Y; State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Sciences, Institutes of Brain Science, Fudan University, Shanghai, China.; MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Disease, Wuxi School of Medicine, Jiangnan University, Wuxi, China., Min JH; Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Joshua V; Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden., Lin J; Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Li Y; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Kreutzmann JC; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Guo Y; Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Xia W; Department of Neurology, Division of Neuroimmunology and Glial Biology, University of California San Francisco, San Francisco, CA, USA., Mohammadi E; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden., Pieber M; Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Suerth V; Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Xia Y; Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Andrusivova Z; Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden., Hugnot JP; Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, Montpellier, France.; Jinfeng Laboratory, Chongqing, China., Kanatani S; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Uhlén P; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Lundeberg J; Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden., Li X; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden., Fancy SPJ; Department of Neurology, Division of Neuroimmunology and Glial Biology, University of California San Francisco, San Francisco, CA, USA., Sarlus H; Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Harris RA; Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden. robert.harris@ki.se., Lund H; Department of Physiology and Pharmacology, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. harald.lund@ki.se.
Source: Nature neuroscience [Nat Neurosci] 2026 Mar; Vol. 29 (3), pp. 617-631. Date of Electronic Publication: 2026 Jan 02.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 9809671 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-1726 (Electronic) Linking ISSN: 10976256 NLM ISO Abbreviation: Nat Neurosci Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-1726
DOI:10.1038/s41593-025-02161-4